|
|
|
|
|
Legal status
Patent not validated
| (51) | INT.CL. | C07K 16/28 | (2006.01) |
| A61K 31/4439 | (2006.01) | ||
| A61P 35/00 | (2006.01) | ||
| A61K 39/395 | (2006.01) |
| (11) | Number of the document | 3498734 |
| (13) | Kind of document | T |
| (96) | European patent application number | 18205542.6 |
| Date of filing the European patent application | 2015-02-03 | |
| (97) | Date of publication of the European application | 2019-06-19 |
| (45) | Date of publication and mention of the grant of the patent | 2021-09-01 |
| (46) | Date of publication of the claims translation |
| (30) | Number | Date | Country code |
| 201461935809 P | 2014-02-04 | US |
| (72) |
MARTINI, Jean-Francais Andre , US
TARAZI, Jamal Christo , US
PERINI, Rodolfo Fleury , US
MAURO, David J. , US
|
| (73) |
Pfizer Inc. ,
235 East 42nd Street, New York, NY 10017,
US
Merck Sharp & Dohme Corp. , 126 East Lincoln Avenue, Rahway, NJ 07065, US |
| (54) | COMBINATION OF A PD-1 ANTAGONIST AND A VEGFR INHIBITOR FOR TREATING CANCER |
| COMBINATION OF A PD-1 ANTAGONIST AND A VEGFR INHIBITOR FOR TREATING CANCER |